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Abstract—The ability to quantify the quality of cardiovascular care critically depends on the translation of recommenda-
tions for high-quality care into the measurement of that care. As payers and regulatory agencies increasingly seek to
quantify healthcare quality, the implications of the measurement process on practicing physicians are likely to grow.
This statement describes the methodology by which the American College of Cardiology and the American Heart
Association approach creating performance measures and devising techniques for quantifying those aspects of care that
directly reflect the quality of cardiovascular care. Methods for defining target populations, identifying dimensions of
care, synthesizing the literature, and operationalizing the process of selecting measures are proposed. It is hoped that
new sets of measures will be created through the implementation of this approach, and consequently, through the use
of such measurement sets in the context of quality improvement efforts, the quality of cardiovascular care will improve.
(J Am Coll Cardiol 2005;45:1147–56.)
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Medicine is experiencing an unprecedented increasedfocus on quantifying and improving the quality of
health care. Although healthcare quality is a multidimen-
sional construct that, as articulated by the Institute of Medi-
cine (1), encompasses concepts of safety, equity, evidence-
based medicine, timeliness of care, efficiency, and patient-
centeredness, the foundation of efforts to improve care is
predicated on measurement. Without the ability to quantify
quality, the opportunity to identify practices that lead to
higher-quality care, and the opportunity to learn how such
care was delivered, quality cannot be improved. Therefore,
developing a framework to measure components of the
quality of health care is of paramount importance.
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have developed a mul-
tifaceted strategy to facilitate the process of improving the
quality of cardiovascular care. The initial phase of this effort
was to create clinical practice guidelines that carefully review
and synthesize the available evidence to better guide patient
care. As articulated in a recent overview of the guidelines
process, the creation of guidelines is but one component of
the ACC’s and the AHA’s commitment to improving the
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ACC/AHA Performance Measures
quality of cardiovascular care (2,3). Because guidelines are
written in a spirit of suggesting diagnostic and/or therapeutic
interventions for patients in most circumstances, a significant
amount of judgment by clinicians is required to adapt the
guidelines to the care of individual patients. Accordingly, the
ACC/AHA guideline recommendations are generated with
varying degrees of confidence based on the available evi-
dence. Occasionally, the evidence supporting a particular
structural aspect or process of care is so strong that failure to
perform such actions reduces the likelihood that optimal
patient outcomes will occur. Quantifying adherence to such
aspects of care can therefore serve as a direct measure of the
quality of care provided (or at least some important compo-
nents of that quality) and as a foundation for quality improve-
ment. In addition, certain outcomes may be so closely
associated with the quality of care provided that they also can
be used to measure healthcare quality. Creating mechanisms
for measuring these opportunities to quantify healthcare
quality in the course of routine practice is an important and
pressing challenge.
This statement describes the methodology by which the
ACC/AHA Task Force on Performance Measures develops
performance measures. By clearly articulating the process by
which performance measures are created, it is hoped that an
understanding of the logic of these measures may be better
appreciated by their users.
The applications of performance measures are designed to
allow a transparent discussion of the quality of health care.
Performance measures are not intended to be an end but
rather a means for measuring and improving care. Specifi-
cally, punitive consequences such as restricting privileges,
contracting selectively, or instituting penalties based on the
performance of health systems or individual caregivers would
undermine efforts to improve quality, particularly because a
natural consequence of such efforts would be for clinicians
and healthcare systems to manipulate the assessment process
so that their performance appears better than it actually is.
The intent of measuring performance is instead to allow
healthcare providers to learn from one another how systems
may be redesigned so that needed processes of care are
applied uniformly to patients who are the most likely to
benefit.
The development and implementation of ACC/AHA per-
formance measures is a multiphase process, consisting of 3
basic phases that are inherent in building a performance
measurement system: construction of the measurement set,
assessment of the feasibility and reliability of data collection,
and measurement of clinicians’ performance. To avoid pit-
falls in application, measurement, and interpretation, the Task
Force identified key methodological areas associated with
each phase that should be considered in developing and
implementing ACC/AHA performance measurement sets.
Analytic issues associated with evaluating and/or monitor-
ing providers via performance data are not discussed in this
statement, although the Task Force recognizes these issues to
be critical to any measurement system. The latter portion of
this statement provides an overview of performance measure
development and implementation (Table 1).
Phase I: Constructing Measurement Sets
Performance systems involve a set of measures that are
targeted toward a particular patient population. From this
high-priority population, a particular period of care can be
identified that lends itself to measurement and improvement.
Developing a set of performance measures entails 5 sequen-
tial tasks.
Task 1: Defining the Target Population and
Observational Period
Quantifying the quality of care often is centered on a specific
disease or its treatment. Thus, performance measures are
designed to assess the care of a cohort of patients and, often,
specific subsets of patients with a given disease. Accurately
defining the target population for a performance measure-
ment system is critical to ensuring the validity of these quality
measures. By being concise in defining the target population,
excessive inclusion and exclusion criteria can be avoided, and
implementation can be more practical. Examples may include
patients discharged from a hospital with heart failure, patients
receiving procedures in specific clinical settings, or the
treatment of acute or chronic aspects of a disease.
Two dimensions of time are relevant to performance
measurement. One dimension is the “period of care” for an
individual patient, during which certain care processes would
be expected to occur. The second dimension is the “period of
observation,” during which a provider treats a number of
individual patients. The period of care has implications for
the specific aspects of care that are relevant and can be
measured (see task 4). Under some circumstances, restric-
tions may be required to collect complete data. For example,
a physician practice group may be interested in assessing the
quality of ambulatory care for patients with heart failure 1
year after an initial diagnosis was made. In this instance, the
target population consists of patients with heart failure, and
the period of care is 1 year after diagnosis. An additional
restriction that patients are continuously enrolled during the
observational period may be required to obtain accurate
information during the entire period of care.
The period of observation for the target population is the
time frame during which sufficient cases accrue to provide
reasonably accurate information about quality. The window
of time selected has implications for both the number of cases
that are available for measurement and the specific aspects of
care that are relevant. For example, observational periods
may be as short as 6 months or as long as 3 years, depending
on the volume of cases within a practice. As longer periods of
observation are considered, changes in technology and delays
in providing analyses may limit the relevance of the data
collected.
Clear, concise, and implementable definitions of the target
population and the observational period that will become the
foundation of the performance measurement set are needed.
In addition, the ongoing efforts of the ACC/AHA Task Force
on Clinical Data Standards (4,5) can provide data definitions
for important clinical variables that are related to perfor-
mance measurement. A sample framework for defining a
target population is provided in Table 2.
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Task 2: Identifying Dimensions of Care
Given the multiple domains of providing care that can be
measured, explicit articulation of which domains are being
quantified by a given performance measure set is needed. All
aspects of the care process, including diagnosis, risk stratifi-
cation and prognosis, treatment, compliance, and patient
reassessment should be considered. As the writing group
plans to develop a measurement set, the group may find it
useful to consider the range of steps needed to deliver optimal
care. Figure 1 illustrates an example of care dimensions for
the ambulatory care of patients with heart failure.
The initial step in rendering care to a patient with heart
failure is to make a proper diagnosis. The next step involves
educating patients about the nature of heart failure and what
to expect regarding treatment (including lifestyle interven-
tions) and prognosis. The third phase of care is to recommend
the initial treatment. It is the evidence for treatment that most
often dominates the work of guidelines committees. Ensuring
that treatment recommendations are followed is the next step
along the path of ideal care and includes teaching patients
techniques of self-management such as weight monitoring
and medication compliance. Finally, serial assessments of
patients’ responses to treatment and a monitor of the status of
their heart failure are needed to continuously optimize the
other aspects of the care of patients with heart failure.
Optimization can be accomplished through the serial assess-
ment of patients’ symptoms, functioning, and quality of life.
Suboptimal health status (eg, symptoms, function, and quality
of life) should trigger a repeated pursuit, following the same
steps outlined above, of opportunities to improve a patient’s
condition. By creating a conceptual model of the dimensions
of care, writing groups can be certain that evidence-based
measures for quantifying each important aspect of care are
developed. The measurement of all phases of ideal care can
readily illuminate the sources of clinical inertia within current
practice. Importantly, guidelines writing groups should re-
view such models to ensure the content validity of their work
(ie, that all important domains are being meaningfully
quantified).
Task 3: Synthesizing and Reviewing the Literature
The goal of task 3 is to identify a set of indicators that are
likely to improve quality. This is accomplished by reviewing
summaries of the evidence-based literature (ie, guidelines)
and existing performance measures from other organizations.
The scientific foundation of clinical medicine is expanding
rapidly. Because performance measures imply that adherence
to these measures is a direct reflection of the quality of care
provided, it is essential that a thorough review and synthesis
of the medical literature be conducted. The critical issues that
TABLE 1. Summary of Performance Measure Development
Task Description
Phase I: Constructing Measurement Sets:
Task 1: Defining the target population
and observational period
Develop a clear, concise, and implementable definition of the sample (eg, adults more than 29 years of age,
discharged alive with a principal diagnosis of heart failure (ICD-9: 398.91, 402.01, 402.11, 402.91, 428.0,
428.1, 428.9), with a length of stay of at least 1 day, excluding patients with an AMI in the previous month
continuously enrolled for 6 months after discharge.
Task 2: Identifying dimensions of care Explicitly define each aspect of care that should be quantified to ensure a valid assessment of the most
meaningful aspects of care. Potential dimensions include diagnosis, risk stratification and patient education,
treatment, self-management, and reassessment of patient’s health status.
Task 3: Synthesizing and reviewing the
literature
Review published literature (including guidelines and other performance measurement systems) with a team of
clinicians and researchers with expertise in meta-analysis.
Task 4: Defining and operationalizing
potential measures
For each measure, determine which data sources are available and define the data elements needed to
construct it (including period of care).
Task 5: Selecting measures for inclusion
in the performance measures set
Present information based on tasks 1–3 to writing group and other relevant individuals, and put in place a
formal mechanism to decide upon the measures that will be selected for inclusion.
Phase II: Determining Measure Feasibility:
Definition of sample Calculate sensitivity and specificity of selection criteria whenever possible. Document sources of case attrition
(eg, medical record never sent, not continually enrolled, died during period of care). Develop an algorithm to
assign patients to providers (eg, primary care provider, specialist) and validate the accuracy of the algorithm.
Feasibility of measures Report validity, reliability, and completeness of collected data. If chart abstraction is used, then interabstractor
reliability needs to be measured; if patient survey is used, then item and unit nonresponse must be measured.
Data lags in identifying and surveying patients need to be assessed.
Phase III: Measuring Performance:
Determining reporting unit Determine at what level information will be reported (eg, physician-level data will typically require longer
accrual period, even if only for internal monitoring).
Determining number and range of
measures
Cost constraints may dictate how many measures can be measured. For quality improvement, how many
measures will be evaluated and/or whether a combined measure is necessary will need to be determined.
Evaluating Performance Caution: To determine whether a provider has “improved” care over time or whether a provider is sufficiently
different from others, a sample size calculation that incorporates the relevant statistical features of the “test”
(within- and between-provider variability, size of test, significance of test) should be undertaken.
ICD indicates International Classification of Diseases; AMI, acute myocardial infarction.
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should be considered when reviewing the literature include
the following:
1. The strength of evidence (ie, multiple efficacy and effec-
tiveness studies consistently demonstrate meaningful ben-
efit on patient outcomes, potentially including Bayesian
analyses (6), that give a strong post-test probability of
benefit) that supports measure inclusion.
2. The clinical relevance of the outcome associated with
adherence to the performance measures (ie, that the out-
comes are meaningful to patients and society and are not
surrogate markers of outcome).
3. The magnitude of the relationship between performance
and outcome (ie, that “significant” improvements in pa-
tients’ health will be realized with greater adherence to
performance).
TABLE 2. Sample Framework for Defining the Target Population
Patient
Characteristic
Category Definition
Acceptable
Responses
Potential Data
Sources Comments
Age Years alive 18–120, unless
otherwise noted
Patient records Because the ACC/AHA guidelines are typical for adult patients,
these performance measures are, in general, meant for
patients 18 years of age or older, unless otherwise noted to
include pediatric patients. This field is best calculated from
birth date and date care was provided if HIPAA regulations
permit collection of the birth date. If not, age should be
calculated and entered.
Gender Sex Female, male Patient records Because the ACC/AHA guidelines define practices that meet
the needs of most patients in most circumstances, the
performance measures will be for both men and women.
Principal diagnosis Diagnosis most responsible
for visit/admission
XXX.XX Patient records,
billing records
Consider including relevant ICD-9 codes that define the group
of patients that are the focus of the study. For prospective
implementations, clinical criteria (eg, positive troponin with
clinical features consistent with MI) could be used.
Principal procedure Primary procedure
performed
XXX.X Patient records,
billing records
Consider including relevant CPT-5/ICD-9 procedure codes that
define the group of patients that are the focus of the study.
Period of care Duration of care
being studied
X months, Y years, etc Patient records,
billing records
Define the time period over which quality will be assessed for
the cohort of patients.
Period of
observation
Duration of time
during which care
is measured
MM/YY–MM/YY N/A This is the time during which cases may accrue for the
observed provider.
Other restrictions Continuous enrollment,
discharged alive, etc
XXXXX Patient records,
billing records
Define any other general restrictions that are needed (eg, if
assessing outpatient care up to 6 months after a hospital
discharge, then patients should be discharged alive and
continuously enrolled for up to 6 months so that data are
complete).
HIPAA indicates Health Insurance Portability and Accountability Act; CPT, Current Procedure Technology; other abbreviations as in Table 1.
Figure 1. Example of care dimensions for ambulatory care for patients with heart failure.
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A review of the medical literature also should acknowledge
the expense of implementing performance measurement. As
such, it is recommended that writing groups consider pursu-
ing the creation of performance measures for only those
aspects of care with the greatest likelihood of providing
meaningful benefit.
As the foundation for the scientific evidence that underpins
the performance measurement set, the appropriate ACC/AHA
Practice Guidelines that are relevant to the topic with which
the writing group has been charged should be reviewed. In
addition, the writing group should perform or have access to
an environmental scan of additional national or international
performance measures for the condition of interest. Finally,
the writing group will benefit by familiarizing itself with any
pending revisions of relevant guidelines. Ideally, perfor-
mance measurement sets would be released at the same time
that guidelines revisions are published.
Clinical Practice Guidelines
Clinical practice guidelines are particularly rich sources of
potential performance measures. The writing group should
have copies of the relevant ACC/AHA Clinical Practice
Guidelines at its disposal. In the event that other guidelines
have been written on the same topic, the writing group should
be informed and should have an opportunity to review these
as well. The following steps are recommended:
1. Identify relevant ACC/AHA and non-ACC/AHA Practice
Guidelines.
2. Review recommendations for each guideline.
3. Determine relevant areas of quality to consider when
developing the performance measurement set.
In general, ACC/AHA Class I and III indications for
therapy identify potential dimensions of care and processes
for performance measurement; however, not all Class I and
III guidelines recommendations should be selected for per-
formance measurement. Specific considerations may include
the following:
● The magnitude of evidence supporting the process of care:
In addition to randomized clinical trials in ideal patients,
effectiveness data demonstrating that the process is related
to improved outcomes in more diverse clinical settings are
of critical importance. Furthermore, in situations in which
the relevance of clinical trial data to the patients that are
being considered for performance measurement is debated,
a mechanism for requesting and reviewing clinical trial
data relevant to the issue at hand ideally should be acquired
and reviewed.
● The relationship of adherence to the performance measure
with clinically meaningful outcomes: The scientific method
is predicated on discovering the pathways by which dis-
eases develop and progress. This process often requires a
focus on surrogate markers of disease progression. For
example, left ventricular ejection fraction or coronary
occlusion may be used to document the progression of
heart failure or coronary disease, yet these characteristics
are less relevant to patients than are survival and health
status. When developing performance measures, writing
groups should consider only those aspects of care associ-
ated with disease outcomes that are relevant to patients and
society. For clinical trials with combined end points,
careful attention to which outcomes were most influenced
by a given process of care and the importance of those
outcomes to patients and society are critical considerations
in selecting potential areas for the development of perfor-
mance measures.
● Separating statistical and clinically significant differences
in outcomes: It is not uncommon for large clinical trials to
identify treatments that have shown small but statistically
significant improvements in outcome. Given the expense of
ultimately collecting potential performance measures, it is
the responsibility of the writing group to make judgments
about the magnitude of the relationship between adherence
to a performance measure and improvements in clinically
meaningful outcomes. Those attributes of care that are
associated with greater absolute (as opposed to relative)
improvements in outcome should be made a priority.
In general, reviewing clinical guidelines annually or bian-
nually is highly recommended. This recommendation reflects
the rapid pace at which knowledge is being generated (3). The
role of performance measures writing groups is not to
perform a primary evaluation of the medical literature; this
task should be undertaken by guidelines writing groups. It is
appropriate—and recommended—that performance measures
writing groups work collaboratively with guidelines writing
groups so that the guidelines may be written with a degree of
specificity that supports performance measurement and that
new knowledge can be incorporated rapidly into performance
measurement.
Existing Performance Measures
An additional important source for identifying potential
performance measures is existing performance measures
endorsed by other groups. Therefore, a review of existing
performance measures being promulgated by other profes-
sional organizations should be conducted. Where possible,
synergy with existing performance measures must be created
so that the burden of data collection may be minimized when
reporting to the different assessors of quality. Upon complet-
ing an environmental scan of performance measures on the
specific clinical topic, the writing group should create a table
describing the performance measurement sets reviewed and
detailing the measure specifications for specific target popu-
lations. Table 3 provides an example of a systematic method
to organize information collected from tasks 1 to 3.
Task 4: Defining and Operationalizing
Potential Measures
Explicit criteria exist for the development of performance
measures so that they can accurately reflect healthcare qual-
ity, including explicit quantification of the numerator and
denominator of potential measures and explicit evaluation of
the interpretability, actionability, and feasibility of the pro-
posed measure. These are critical steps to take before the
quality of care can be measured. Upon determining the target
population and care period and reviewing pertinent scientific
evidence on the topic, the writing group should operationalize
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the areas of quality identified in task 3. This is the most
time-consuming and challenging task because it involves
translating recommendations to specific measures. To accom-
plish this task, 3 key items for constructing each measure
should be defined as follows.
Defining the Period of Care
The writing group should specify the time period during
which each performance measure is to be evaluated. For
example, some processes of care are required to be carried out
within 24 hours of admission, others before discharge, and
still others within 3 months of discharge. The writing group
should give due consideration to the circumstances of routine
clinical practice when specifying the period of care. For
example, although aspirin should be prescribed within 24
hours of a heart attack and beta-blocker use should be started
during initial heart failure hospitalization, maximizing the
beta-blocker dosage may be better completed in the outpa-
tient setting rather than at the time of hospitalizing a patient
for decompensated heart failure. In the case of a heart attack,
it would be appropriate to assess performance upon hospital
discharge. In the case of maximizing beta-blocker dosage in
patients with heart failure, however, information may not be
feasibly collected until 3 months after discharge.
Specifying the Denominator
The denominator of a performance measure refers to the
target population that is eligible for the assessment of each
TABLE 3. Sample Summary Information
Dimension of
Care Recommendations and Guidelines
Potential
Quality Area
Site of
Care
Existing
Measures
Initial recognition
and treatment
ACC/AHA Class I: A dose of 160 to 325 mg of aspirin
should be given on day 1 of acute MI and continued
indefinitely.
Aspirin on arrival Inpatient CMS, JCAHO, VA
ACC/AHA Class I: An ECG should be obtained and
interpreted within 10 min of arrival in the emergency
department for all patients with suspected acute
ischemic-type chest discomfort.
ECG on arrival Inpatient VA
Hospital
treatment
ACC/AHA Class I: Primary PCI: As an alternative to
fibrinolytic therapy in patients with AMI and ST-segment
elevation or new or presumed new LBBB who can undergo
angioplasty of the infarct-related artery within 12 hours of
symptom onset or beyond 12 hours, if ischemic symptoms
persist and if performed in a timely fashion* by those
skilled in the procedure† and supported by experienced
personnel in an appropriate laboratory environment‡
Appropriate primary PCI Inpatient JCAHO, CMS, VA
Pharmacotherapy ACC/AHA Class I: Beta-blockers: Patients without a
contraindication to beta-blocker therapy who can be treated
within 12 hours of onset of infarction, irrespective of
administration of concomitant fibrinolytic therapy
Beta-blocker on admission Inpatient CMS, JCAHO, VA
Risk stratification
and treatment
ACC/AHA UA/NSTEMI Guidelines: Biomarkers of cardiac
injury should be measured in all patients who present with
chest discomfort consistent with ACS. A cardiac-specific
troponin is the preferred marker, and if available, it should
be measured in all patients. In patients with negative
cardiac markers within 6 hours of the onset of pain, another
sample should be drawn in the 6- to 12-hour time frame
(eg, at 9 hours after onset of symptoms).
Early risk stratification Inpatient
Secondary
prevention
ACC/AHA Class I: Patients with LDL-cholesterol levels
greater than 100 mg/dL should be placed on drug therapy
on hospital discharge, with preference given to statins
(Level of Evidence: A). Patients with LDL less than 100
mg/dL or unknown LDL should be prescribed statins on
hospital discharge (Level of Evidence: B).
Lipid-lowering therapy on
discharge
Inpatient VA
AHA Secondary Prevention Guidelines Outpatient
Provider–patient
interaction
Patient-presented alternative
treatment options
Inpatient
Long-term
treatment
Symptom & Activity Assessment: Regular assessment of
patients’ angina symptoms and levels of activity is
recommended.
Patient assessment with or
without risk stratification
Outpatient ACC/AHA/AMA
Physician Consortium
CMS indicates Centers for Medicare and Medicaid Services; JCAHO, Joint Commission on Accreditation of Healthcare Organizations; VA, Department of Veterans
Affairs; AMI, acute myocardial infarction; LBBB, left bundle-branch block; PCI, percutaneous coronary intervention; ACS, acute coronary syndromes.
*Performance standard: balloon inflation within 90 plus or minus 30 minutes of admission.
†Individuals who perform more than 75 PCI procedures per year.
‡Centers that perform more than 200 PCI procedures per year and have cardiac surgical capability.
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measure. In defining the denominator, the writing group
provides direction for data to be collected and identifies
consistent sources for information. Occasionally, the denom-
inator will exclude subsets of patients within the target
population and the dimension of care for the performance
measure. This often arises when physicians provide a ratio-
nale for not applying the performance measure or when
emerging evidence dictates that an alternative treatment
strategy may be appropriate but evidence is insufficient to
support that treatment as satisfying the performance measure.
For example, in 2003, evidence was insufficient to recom-
mend that angiotensin-receptor blockade be used for all
patients with congestive heart failure, particularly if they
could tolerate angiotensin-converting enzyme (ACE) inhibi-
tor medications. If a physician recommends angiotensin-
receptor blockade, however, then treatment with an ACE
inhibitor may not be necessary. In this situation, when
sufficient uncertainty exists in the medical literature to
support the use of angiotensin-receptor blockers as an alter-
native to ACE inhibitors, then patients treated with angioten-
sin-receptor blockers may be excluded from the denominator
so that they neither count as fulfilling nor as not fulfilling the
performance measure.
Clarity of the denominator is needed so that the selected
performance measures are clinically relevant. A tension exists
between specificity and inclusivity of the denominator. When
considering the most appropriate denominator, the writing
group should entertain issues of the population’s magnitude
(ie, the larger the number of eligible patients, the more
important the performance measurement set), variability in
care, and the association with outcome of greater adherence
to the potential performance measure.
Specifying the Numerator
The numerator of a performance measure indicates the subset
of the denominator that has had the performance measure
met. Patients from the denominator enter the numerator if
documentation that the performance measure has been exe-
cuted is available. Alternatively, if the quality measure is
continuous (eg, blood pressure), then the performance mea-
sure can be either a mean (or median or other summary)
across the patients who are eligible for the measure or
dichotomized as meeting a prespecified desirable goal. Table
4 provides an example of the definition of a performance
measure for a target population of adults discharged alive
with a principal diagnosis of acute myocardial infarction.
Task 5: Selecting Measures for Inclusion in the
Performance Measurement Set
On the basis of the information collected, the writing group will
be able to choose from a range of measures. Selecting which
potential measures to endorse should involve considering the
interpretability, actionability, and feasibility of implementing
each measure. Interpretability reflects the degree with which a
practitioner is likely to understand what the results mean and can
take action if necessary. Actionability represents an assessment
of the degree to which a practitioner can influence the quality of
the care being delivered by the health system. Because the
purpose of quality assessment is to improve care, it is important
that the performance measure be under the locus of control of the
entity being assessed. Finally, the feasibility of collecting the
data required for the performance measure must be assessed.
Feasibility addresses whether the required data can be typically
abstracted from patient charts through easily implemented pro-
spective or retrospective data collection systems or from national
registries/databases that are readily available.
To assist in the selection process, it is recommended that the
writing group pursue a formal strategy of evaluating potential
measures. A systematic determination of the usefulness, speci-
fication, and likely feasibility of implementation will focus
discussion on the advantages and disadvantages of each mea-
sure. Determining measure feasibility, a critical component of
the ACC/AHA’s multiphasic approach to building a
performance-measurement system, is described in phase II. Such
a determination can be assessed through a survey of writing
group members and the parent committee of the ACC/AHA
Task Force on Performance Measures. In addition, when re-
sources permit, extension of the survey to practitioners and
healthcare systems would be an excellent strategy for assessing
the feasibility of a measurement set before its initial publication.
A sample survey form (Figure 2) and a guide for its completion
(Figure 3) are presented here. Rules for selecting performance
measures should be decided upon before the survey is
completed.
After digesting and integrating the feedback from these initial
surveys, a final proposed measurement set is developed. At this
point, a broader review of the performance measurement set
occurs. This parallels the approach used in the review of
proposed guidelines (2), whereby disease experts, other organi-
zations, representatives from the ACC Board of Trustees and the
AHA Scientific Advisory Committee, and the public are invited
to review the proposed measurement set during an established
TABLE 4. Example of Measure Specifications for Daily Aspirin
Use for Adults Discharged Alive With Acute Myocardial Infarction
Performance
Measure Daily Aspirin Use
Description of the
measure
75 to 325 mg daily should be used routinely by all
patients with acute and chronic ischemic heart
disease with or without manifest symptoms in the
absence of contraindications
Clinical
recommendation
Aspirin is effective secondary prevention for survivors
of myocardial infarction against reinfarction and
death
Period of care At the time of hospital discharge and continued
throughout the period of care being assessed
Denominator Patients 18 years of age or older discharged alive
with a principal diagnosis of acute myocardial
infarction AND who do not have a contraindication to
aspirin use, including x, y, and z
Numerator* Number of patients in the denominator whose
medical record documents a prescription for daily
aspirin at discharge
Data sources Inpatient medical record; flow sheet
Methods of reporting Proportion of a physician’s eligible patients recorded
as receiving aspirin (standard error)
* Mean or median if measure is continuous.
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comment period. The writing group then responds to all com-
ments and completes the performance measurement set (ie,
phase I).
At the completion of phase I, the initial work of the perfor-
mance measures writing group draws to a close; however,
additional work, as described in phases II and III, is necessary.
At the conclusion of phases II and III, it is expected that the
writing group will reconvene to review initial results, trouble-
shoot observed difficulties, and, if necessary, refine the mea-
sures. The writing group also will convene to update those
measures when ACC/AHA guidelines are updated. These steps
necessitate that the writing groups for performance measures
serve as “living committees” so that reviews and revisions of
both the specifications of existing measures and the introduction
of new measures can occur in a timely manner, again mirroring
the evolution of current guidelines committees (3).
Phase II: Determining Measure Feasibility
After potential measures are selected, formal evaluations of
the feasibility of assessing performance with each measure
should be pursued. Within the target population, the writing
group must consider 2 levels of assessment: (1) how well they
can identify their sample and (2) how well they can measure
the data items for each member of the sample. Identifying a
test population depends on the design (eg, prospective data
collection or retrospective data collection, inpatient or
ambulatory-based cohorts) and the intended implementation
of the performance measures in clinical practice. During this
evaluation process, explicit efforts to define the sensitivity
and specificity of the sample identification procedure should
be determined. For example, if administrative data will be
used to initially identify the sample, then medical records data
or direct patient assessments may be used to validate the
diagnosis in patients identified as having the disease and its
absence in a population of patients not identified as having
the target condition.
Once the sample is identified and a provider or providers
associated with each patient determined, the Task Force recom-
mends that the validity, reliability, and completeness of each
data item be assessed. The methodology for assessing feasibility
depends on the available data sources. For example, if medical
records data are used, then the frequency of missing patient
records should be recorded. In addition, the reliability of medical
record chart abstraction should be studied and assessed. If items
cannot be abstracted with sufficient reliability, then dropping the
measure from the measurement set should be considered.
Alternatively, if patient survey data are used (eg, to quantify
patients’ health status and compliance with recommendations
such as exercise or smoking cessation), then the frequency and
distribution of patient nonresponse should be assessed. The time
Figure 2. Sample rating form. Adapted
from the Q-SPAN-CD collaboration.7
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between an index-defining event and surveying a patient should
be assessed to determine whether it is feasible for patients to
recall needed information. Individual items within the survey
should be examined in terms of completeness and clinical logic,
reliability, and responsiveness so that the results are a valid
reflection of patient outcomes.
If administrative data are used, then the lag time between
patient events and recording the events in the files should be
assessed. When data are missing, especially those based on
diagnostic tests, analytic methods based on realistic scientific
assumptions should be used to make inferences.
Phase III: Measuring Performance
Because the choice of a performance measurement system
ultimately depends on its intended use, the Task Force recom-
mends that researchers decide a priori both the reporting unit and
the number and range of measures (many measures, a composite
measure, or both) to be reported. Although all measurements
will be made at the patient level, it is important to determine
whether the reporting unit will be at the individual physician
level, the group level, the health plan level, and so forth. The
ACC/AHA Task Force on Performance Measures intends for its
measurement sets to be used by physicians to improve perfor-
mance at the physician level. It is recognized, however, that for
accurate estimates of performance to be obtained, a sufficient
number and broad array of cases will be required to prove that
providers have indeed “improved.” Furthermore, many interven-
tions needed to improve performance will be system-level
interventions, and aggregating individual provider data will be
needed both to assess the performance of systems of care and to
monitor changes in performance over time. Assistance from
individuals trained in statistics is critical for the successful
aggregation of such data.
Conclusion
Quantifying clinical performance is a necessary step for improving
the quality of health care. Although many entities are involved in
creating methods for quantifying healthcare quality, the ACC and
the AHA have joined forces to advance the field of quality
assessment through the creation of performance measurement sets.
(Table 1 summarizes the steps described to achieve this.)
An important consideration, although not discussed in this
statement, in implementing a performance measurement relates to
the frequency of measurement. This is a particularly challenging
Figure 3. Sample rating form guide.
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issue and reflects a tension between the desire to provide rapid
feedback on the one hand and a need to have accurate data on the
other. The “accuracy” of data is a design issue that is affected by the
volume of eligible cases, the variability in clinician performance,
and the anticipated changes over time. Consequently, the timing of
data reporting is likely to be greatly influenced by the intended
purpose of such reporting. If reporting is for the sole use of the
practitioner, then more frequent reporting intervals are appropri-
ate, under the presumption that every case is an opportunity to
improve the quality of care; however, if other credentialing,
purchasing, or regulating entities are to review such reports, then
greater statistical accuracy is needed and longer intervals be-
tween reporting periods are indicated.
It is hoped and anticipated that through the implementation of
this methodological framework, new sets of performance measures
will be created for cardiovascular care, and that through their use,
the quality of cardiovascular care will improve (7).
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